Page 27 - Read Online

Tsai et al. Vessel Plus 2021;5:9 Vessel Plus
DOI: 10.20517/2574-1209.2020.73

Review Open Access

Stem cell therapy in stroke

Sheng-Tzung Tsai , Chien-Hui Lee , Shinn-Zong Lin , Dah-Ching Ding 2,3
1
1
1
1 Bioinnovation Center, Tzu Chi foundation, Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation,
Tzu Chi University, Hualien 970, Taiwan.
2 Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, Tzu Chi University, Hualien
970, Taiwan.
3 Institute of Medical Science, College of Medicine, Tzu Chi University, Hualien 970, Taiwan.

Correspondence to: Dr. Dah-Ching Ding, MD, Ph.D., Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital,
Buddhist Tzu Chi Medical Foundation, Tzu Chi University, No. 707, Chung-Yang Rd., Sec. 3, Hualien, 970, Taiwan, R.O.C.
E-mail: dah1003@yahoo.com.tw

How to cite this article: Tsai ST, Lee CH, Lin SZ, Ding DC. Stem cell therapy in stroke. Vessel Plus 2021;5:9.
http://dx.doi.org/10.20517/2574-1209.2020.73

Received: 17 Nov 2020 First Decision: 31 Dec 2020 Revised: 12 Jan 2021 Accepted: 19 Jan 2021 Published: 7 Feb 2021
Academic Editors: Elisa F. M. Ciceri, Aaron S. Dumont Copy Editor: Yue-Yue Zhang Production Editor: Xi-Jun Chen

Received: First Decision: Revised: Accepted: Published: x
Abstract
Science Editor: Copy Editor: Production Editor: Jing Yu Stroke is the leading cause of neurological disability in adults worldwide and involves the significant impairment of
sensory-motor function caused by cerebral ischemia and subsequent neuronal death. Owing to a lack of medical
or surgical treatments to improve neurological function and neurogenesis, chronic stroke places a huge burden
on patients, their families, and society. Over the past twenty years, increasing evidence from translational and
clinical research has demonstrated the potential effectiveness of hematopoietic growth factors and stem cell
administration or transplantation in the treatment of stroke. In particular, these studies have included granulocyte
+
colony-stimulating factor, mesenchymal stem cells, autologous CD34 peripheral blood stem cells, umbilical cord
blood stem cells, and autologous adipose-derived mesenchymal stem cells. It is therefore important to consider
the safety of these putative therapies whilst achieving the maximum benefit for patients with chronic stroke in
terms of the route of administration and stem cell numbers. In this review, we discuss current evidence and the
progress that has been made in our hospital, which paves the way for the next neurogenesis therapy for chronic
stroke.

Keywords: Stem cells, stroke, therapy, neural stem cells, mesenchymal stem cells

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.vpjournal.net